Drug intelligence / Profile preview

gsk2392105a

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK2392105A is an investigational prophylactic vaccine developed by GSK as an immunostimulant for the prevention of staphylococcal infections. It is designed to stimulate the immune system to provide protection against Staphylococcus aureus, a common cause of hospital- and community-acquired infections. The drug has been evaluated in phase 1 clinical trials for safety, reactogenicity, and immunogenicity in healthy adults[1][2][4].

Beyond the preview

Go deeper on gsk2392105a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gsk2392105a.

Explore the full profile